What is Ozempic, and how is it different from retatrutide?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk and approved by the FDA in December 2017 to improve blood-sugar control in adults with type 2 diabetes. It is important to be precise here: Ozempic is the diabetes brand of semaglutide. The same molecule, formulated at a higher 2.4 mg weekly dose, was approved separately as Wegovy in 2021 for chronic weight management in adults with obesity or overweight plus a weight-related condition. So when people compare "retatrutide vs Ozempic," the headline weight-loss numbers they have in mind usually come from the obesity (Wegovy) program, not from Ozempic's diabetes label.
Retatrutide, developed by Eli Lilly under the code name LY3437943, targets a broader set of receptors. While semaglutide activates only the GLP-1 receptor, retatrutide simultaneously activates three: GLP-1, GIP, and glucagon. That additional glucagon-receptor component is the mechanistic headline — glucagon-receptor activity is associated with increased energy expenditure and reduction of hepatic (liver) fat, effects that single-agonist semaglutide does not produce through the same pathway.
The difference that matters most today, though, is regulatory rather than molecular. Ozempic is an approved medicine with an established supply chain and years of real-world prescribing data in diabetes. Retatrutide, as of 2026, remains investigational: it has no FDA approval for any indication and is available only within Eli Lilly's Phase 3 TRIUMPH clinical-trial program. Any comparison has to start from that asymmetry.
Which produced more weight loss in clinical trials?
In its Phase 2 obesity trial, retatrutide at the 12 mg dose produced a mean body-weight reduction of approximately 24.2% at 48 weeks — one of the largest figures reported for any pharmacological weight-loss agent to date. The trial studied weekly doses of 1, 4, 8, and 12 mg, with a lower 2 mg starting dose used to mitigate gastrointestinal effects during titration. For the semaglutide comparison, the relevant weight-loss number comes from STEP 1, which tested semaglutide at 2.4 mg — the dose marketed as Wegovy, not the Ozempic diabetes dose — and reported a mean reduction of approximately 14.9% at 68 weeks versus about 2.4% on placebo.
Two caveats are essential before reading those numbers as a ranking. First, the brand framing: the ~15% figure belongs to semaglutide as Wegovy at 2.4 mg in an obesity population. Ozempic itself is approved for type 2 diabetes, and its labeled doses top out at 2 mg weekly; people should not infer that Ozempic is an approved weight-loss drug. Second, the trials are not comparable head-to-head — retatrutide's figure is from a Phase 2 obesity study at 48 weeks, while semaglutide's is from a Phase 3 obesity trial at 68 weeks, in different populations with different titration schedules. The percentages are not directly subtractable.
A larger early-phase figure for retatrutide does not guarantee superiority once Phase 3 is complete — effect sizes tend to moderate as trial populations broaden and studies run longer. Semaglutide, by contrast, has a completed pivotal trial behind its number plus years of real-world prescribing data that retatrutide has not yet had the opportunity to accumulate. Treat the comparison as "what each drug did in its own study," not as a verdict.
How do the responder rates compare?
Responder rates — the share of participants who hit specific weight-loss thresholds — add useful texture beyond the average. In the retatrutide Phase 2 trial, the 12 mg group reported that 100% of participants lost at least 5% of body weight, 93% lost at least 10%, 83% lost at least 15%, and roughly two-thirds reached at least 20% at 48 weeks. Those are unusually high response proportions, though from a smaller, earlier-stage study.
In STEP 1, semaglutide at 2.4 mg (the Wegovy dose) reported 86.4% of participants losing at least 5% of body weight, 69.1% losing at least 10%, and 50.5% losing at least 15% over 68 weeks. These are strong, durable responder rates from a completed Phase 3 obesity trial that supported an FDA approval — a different and more mature class of evidence than a Phase 2 readout.
The same warning applies as with the averages: these proportions come from separate trials with different designs, durations, and populations, so the response curves are not directly comparable. They describe each compound within its own study, and the retatrutide figures in particular still have to be confirmed at Phase 3 scale before they can carry the same weight as semaglutide's.
What about liver fat and metabolic-liver disease?
Liver fat is where retatrutide's glucagon arm shows up most strikingly in the data so far, and it is a genuine point of differentiation from Ozempic. A separate Phase 2a trial studied retatrutide specifically in metabolic dysfunction-associated steatotic liver disease (MASLD, the condition formerly framed as non-alcoholic fatty liver disease). At 24 weeks the higher doses produced a relative reduction in liver fat of roughly 81% at 8 mg and roughly 82% at 12 mg, with the majority of participants on those doses reaching normal liver fat, versus essentially no change on placebo.
Those are large reductions, but context matters. This was an early-stage, 24-week study measuring liver fat on imaging — a biomarker — not a trial proving retatrutide reverses fibrosis, improves liver-related clinical outcomes, or earns a liver-disease indication. Retatrutide is not approved for MASLD or for anything else, and these findings have not been confirmed in a completed Phase 3 program.
Semaglutide also improves hepatic steatosis and is being studied in metabolic liver disease, but as with retatrutide, its approved uses are diabetes (Ozempic) and weight management (Wegovy), not liver disease per se. For anyone with fatty-liver concerns, the practical takeaway is the same regardless of compound: liver enzymes and metabolic markers should be monitored by a clinician, not self-managed off trial headlines.
How do they compare on cardiovascular and glycemic outcomes?
This is where Ozempic's diabetes pedigree is its clearest advantage. Cardiovascular-outcomes trials are large, multi-year studies that count actual heart attacks, strokes, and cardiovascular deaths rather than weight or glucose — the gold standard for showing a drug changes hard clinical events, not just numbers on a chart. In SUSTAIN-6, in adults with type 2 diabetes at high cardiovascular risk, semaglutide reduced the primary composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke with a hazard ratio of 0.74 — roughly a 26% relative reduction.
On glycemic control, Ozempic's entire reason for approval is improving blood-sugar control in type 2 diabetes, and it is titrated for that purpose: 0.25 mg to initiate for the first four weeks, then 0.5 mg, then 1 mg, and up to 2 mg weekly as needed. Retatrutide's Phase 2 obesity trial reported improvements in glycemia, blood pressure, and lipids as secondary endpoints, consistent with its class — but these were exploratory secondary findings, not the basis of any approved glycemic indication.
Retatrutide has no comparable cardiovascular-outcomes data. As an investigational compound it has not completed — and at the time of writing has not reported — a dedicated cardiovascular-outcomes trial, so there is no evidence yet that it reduces heart attacks or strokes. Its trials did note dose-dependent increases in heart rate, a signal any future cardiovascular-outcomes study will need to characterize. Until that evidence exists, semaglutide is the only one of the two with proven cardiovascular benefit.
Dosing and availability: prescription versus trials-only
Ozempic is a prescription medicine dispensed through licensed pharmacies, with a defined titration schedule designed to balance efficacy against gastrointestinal tolerability: 0.25 mg once weekly to start (a non-therapeutic initiation dose for the first four weeks), stepping up to 0.5 mg, then 1 mg, and up to a 2 mg weekly maximum. A prescriber decides the target dose based on glycemic response and tolerability.
Retatrutide has no approved dose because it has no approval. Its trial protocols escalated weekly doses up to 12 mg, typically starting at 2 mg to soften early GI effects, but these are research regimens, not labeled directions. The only lawful route to receive retatrutide is enrollment in a clinical trial under the TRIUMPH program. Material marketed online as "research" retatrutide is explicitly labeled not for human use, sits outside regulated identity, purity, and sterility standards, and does not come from an approved supply chain.
So the practical availability gap is stark. If improved glycemic control is the goal today, Ozempic is a prescribable, well-characterized option; if substantial weight loss is the goal, the approved semaglutide option is Wegovy, prescribed by a clinician. Retatrutide is, for now, available only to trial participants. Any medication decision must involve a licensed clinician who can weigh your complete medical history.
How do the side effects compare?
Both compounds share the same dominant adverse-event signature: dose-dependent gastrointestinal effects — nausea, diarrhea, vomiting, and constipation — that tend to diminish as the dose is escalated gradually. This similarity is expected because both activate the GLP-1 receptor, which slows gastric emptying. Gradual titration (Ozempic's 0.25 mg start; retatrutide's 2 mg trial start) is the standard tool for managing these effects in both.
Retatrutide trials additionally reported dose-dependent increases in resting heart rate. Its long-term safety profile is inherently thinner than semaglutide's because it has not completed Phase 3 or accumulated the post-market pharmacovigilance data semaglutide has built over nearly a decade of approved use across millions of patients. That asymmetry in evidence depth is itself a clinically meaningful difference between the two compounds.
None of this is a substitute for individualized assessment. Side-effect risk depends on the person, the dose, the titration pace, and concurrent medications — which is exactly the kind of judgment a prescribing clinician makes, and exactly why these decisions cannot be made off a comparison table.
TRIUMPH and what comes next for retatrutide
Retatrutide's path to any approval runs through TRIUMPH, Eli Lilly's Phase 3 program. It comprises four trials enrolling more than 5,800 participants across distinct populations: obesity, obesity with type 2 diabetes, severe obesity with cardiovascular disease, and obesity with knee osteoarthritis. The breadth of that program signals the indications Lilly is pursuing, but signals are not approvals.
As of 2026 the TRIUMPH trials are still ongoing. That means there is no approval date, no labeled dose, and no completed Phase 3 efficacy or safety dataset for retatrutide — everything currently known comes from Phase 2 and earlier work. The strong Phase 2 weight-loss and liver-fat figures are the reason the program is being run, not proof of what Phase 3 will show.
For now, the honest summary is that retatrutide is a promising but unproven investigational compound, while Ozempic is an approved, well-characterized diabetes therapy with cardiovascular-outcomes data behind it. Those are different categories of evidence, and the gap closes only if TRIUMPH reports and a regulator acts on it.
Which should you consider?
A comparison page cannot answer this for you. The right choice depends on your diagnosis, your goals, your other conditions and medications, and your tolerance for side effects — all of which a licensed clinician is positioned to weigh and a web page is not.
What can be said plainly is the framing. If the goal is glycemic control in type 2 diabetes today, Ozempic is an approved, prescribable option with cardiovascular-outcomes data in that population. If the goal is weight management, the approved semaglutide option is Wegovy at 2.4 mg, not Ozempic. Retatrutide, however striking its early figures, is not an option you can choose outside a clinical trial, because it is not approved.
The constructive move is to bring the actual numbers — and this distinction between approved and investigational — to a clinician who can map them onto your situation. They can also tell you whether a relevant TRIUMPH trial is enrolling, if a trial pathway is something you want to explore.
Tracking either compound on PeptidePanel
Whichever agent a clinician prescribes, the day-to-day management work is the same: logging doses, monitoring the biomarkers that reflect protocol performance (HbA1c, fasting glucose, weight trend, lipids, liver enzymes), and catching side effects early. PeptidePanel is the neutral tracking layer for that record-keeping — it logs the protocol your prescriber sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, supply, or endorse any compound. It is a monitoring tool for protocols prescribed and supervised by a qualified clinician.